As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Treatment for dementia focuses on managing symptoms and improving quality of life. Options may include medications to slow disease progression, as well as therapies like occupational, physical ...

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

(“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s ty ...

Previous research has associated sleep medications with other health risks, such as falls, fractures, car accidents, and ...

Cognitive problems like more diminished attention, but better immediate recall and memory may help predict Lewy body dementi ...

(“Alpha”) of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets ) (“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is ...

Lisa Ricciardi, president and CEO of Cognition Therapeutics was recently a guest on Benzinga's All-Access. Cognition ...

Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...

(“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is ...